

**THIS INFORMATION IS ADDRESSED TO HEALTHCARE
PROFESSIONALS WHO TAKE CARE OF PATIENTS
TREATED WITH MD1003 / QIZENDAY®
(biotin 100 mg, hard capsule)**

MD1003 / QIZENDAY is developed and used in adults for the treatment of progressive multiple sclerosis (primary or secondary).

WARNING

Some laboratory tests may potentially be distorted by biotin.

Biotin may interfere with some immunoassay methods that use a biotinylated reagent i.e. based on a biotin/streptavidin interaction (including tests that could be required in an emergency situation). Please refer to the list of parameters below (non-exhaustive). Interference may also occur with some tissue pathology examinations.

Depending on the method used, results can be falsely low (e.g. sandwich immunoassays) or falsely high (e.g. competitive immunoassays). This may lead to misdiagnosis and missed diagnosis.

Alternatives are available:

Not all analysers use biotin/streptavidin method for immunoassays. This depends on the parameter analysed, the analyser manufacturer, the reagent cartridges used in the analyser.

Learn more about biotin interference with:

[Sandwich Immunoassays](#)

[Competitive Immunoassays](#)

Information to the physician prescribing/interpreting a laboratory test

Check with the laboratory if biotin interferes with the assay method used for this laboratory test.

The laboratory should be informed of the potential interferences between biotin and immunoassays.

Remind the patient to carry and show their card to any healthcare professional they see.

Information to the healthcare professionals from the laboratory

Check if biotin interferes with the assay method used for the prescribed laboratory test.

Not all analysers use biotin/streptavidin method for immunoassays. This depends on the parameter analysed, the analyser manufacturer, the reagent cartridges used in the analyser.

If biotin interferes with the assay method used for this laboratory test, the test should be repeated using an assay not subject to interference by biotin.

When no alternative method is available, a wash-out period is required before collecting the samples. The wash-out period depends on a variety of factors, so no specific recommendation can be made across all individuals and tests.

TREATMENT WITH MD1003 / QIZENDAY MAY INTERFERE WITH SOME LABORATORY TESTS (non-exhaustive list)

ANAEMIA EPO Ferritin Folate Vitamin B12 CARDIOLOGY BNP CK-MB D-Dimer Myoglobin NT-proBNP Troponin I Troponin T ENDOCRINOLOGY ACTH AMH Androstenedione Cortisol C-Peptide DHEA-s Estradiol Estriol, unconj. FSH, LH HbA1c	ONCOLOGY ACE AFP β -microglobuline BR 27.29 CA 125 CA 15-3 CA 19.9 CA 72-4 Cyfra 21-1 HE4 HER-2/neu Gastrin NSE PAP ProGRP PSA S100 sFit-1 TPS BONE METABOLISM Anti-CCP Beta cross Laps	INFECTIOUS DISEASES Ag HBe Ag HBs Anti-HAV Anti-HBc Anti-HBc IgM Anti-Hbe Anti-HBs Anti-HCV 2 Anti-HIV 1/2 C. Difficile Toxin A&B CMV IgG, IgM H. Pylori IgG Herpes I & II IgG HIV Ag p24 HIV Ag Confirm. HIV Combo HSV-1/2 IgG Rubella IgG, IgM Syphilis Toxo Avidity Toxo IgG, IgM	LIVER FIBROSIS Hyaluronic acid PIIINP TIMP-1 DRUGS OF ABUSE/ TOXICOLOGY 6-Acetylmorphine Acetaminophen Amphetamines Barbiturates Benzodiazepines Caffeine Cannabinoids Cocaine metabolite Ecstasy Methadone Methadone metabolites, EDPP Methaqualone Methotrexate Opiates Phencyclidine Propoxyphene
--	---	---	--

HCG	Osteocalcin	THERAPEUTIC DRUGS	Salicylate
hGH	PTH	Carbamazepine	Tricyclic antidepressants
IGF-1	P1NP	Cyclosporine	
IGFBP-3	Pyrilinks-D	Digitoxine	
Inhibin A	Vitamin D	Digoxine	
Insulin	SEPSIS / INFLAMMATION	Gentamicin	
PAPP-A	C1 inhibitor	Lidocaine	
PIGF	C3, C4	Lithium	
Progesterone	CRP	Mycophenolate	
Prolactin	IgA, IgE, IgG, IgM	Phenobarbital	
SHBG	IL6, IL8, IL10	Phenytoin	
Testosterone	LBP	Procainamide	
Anti TG	Prealbumin	Sirolimus	
Anti TPO	Procalcitonin	Sodium Valproate	
Anti-TSHr	TNF- α	Tacrolimus	
Calcitonin	Transferrin	Theophylline	
T3, FT3		Tobramycin	
T4, FT4		Vancomycin	
TBG			
Tg			
TSH			
T-Uptake			

Reporting of suspected adverse events

Reporting suspected adverse events is important. It allows continued monitoring of the safety profile of the medicinal product. Healthcare professionals are asked to report any suspected adverse event to their clinical center reporting system or to their national reporting system.



For further information, contact us at medinfo@medday-pharma.com | Legal notices

UDI: COM-011-003

Last update: 04/05/2018